[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"blood-clot\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:blood-clot":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,77],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100620892","michigan-initial-experience-using-tigertriever-for-thrombectomy-100620892",false,"NCT07363525","Michigan Initial Experience Using Tigertriever for Thrombectomy","MIGHTY","Inclusion Criteria:\n\n1. Patients admitted with large vessel occlusion (LVO) and treated with the Tigertriever, as per the approved indication.\n2. Tigertriever was used as the first line treatment in the target vessel.\n3. A signed informed consent.\n4. Age ≥ 18.\n\nExclusion Criteria:\n\n-1. Evidence of acute brain hemorrhage on NCCT or MR at admission. 2. Prior hemorrhage, stroke, thrombolysis, and\u002For endovascular therapy in the last 3 months.\n\n3\\. pre-stroke disability (pre-stroke mRS ≥ 2).","ALL","18 Years",{"count":19,"type":20},150,"ESTIMATED","90 Days","OBSERVATIONAL","The purpose of this research study is to collect data about the effectiveness (i.e. how the device works) and safety (how safe it is to use such a device) of the Tigertriever in restoring blood flow by removing thrombus (or blood clot) from a large intracranial vessel (blood vessel in the brain) in patients experiencing ischemic stroke within 8 hours of symptom onset.",[25,26,27],"Blood Clot","Thrombectomy","Ischemic Stroke",[29,30,31,32],"thrombus","Clot","Device","Stroke","RECRUITING","2026-05-06",{"date":36,"type":37},"2026-05-08","ACTUAL",{"date":39,"type":37},"2026-01-15",{"date":41,"type":20},"2028-12-31",{"name":43,"class":44},"Henry Ford Health System","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100546356","phase-3-reducing-gastrointestinal-bleeding-with-proton-pump-inhibitor-therapy-in-acute-venous-thromboembolism-100546356","NCT06393868","Reducing Gastrointestinal Bleeding With Proton Pump Inhibitor Therapy in Acute Venous Thromboembolism","Reducing Gastrointestinal Bleeding With Proton Pump Inhibitor Therapy in Acute Venous Thromboembolism: Pilot Randomized Study (RADIANT Study)","Inclusion Criteria:\n\n1. Male or female 65 years or older at the time of enrolment. Enrolment is limited to older adults as age is an important non-modifiable risk factor for bleeding. This will ensure the study population includes participants who may be more likely to benefit from omeprazole (compared to those with no risk factors) because all participants will have at least 1 risk factor for bleeding.\n2. Newly diagnosed VTE which includes VTE at any site such as (but not limited to) DVT of upper or lower limbs, PE, cerebral vein thrombosis, portal vein thrombosis, other splanchnic vein thrombosis.\n3. Planned for 3 months (90 days) or more of therapeutic anticoagulation with any anticoagulant.\n4. Patient or delegate is able and willing to comply with follow-up examinations contained within the consent form.\n\nExclusion Criteria:\n\n1. Therapeutic anticoagulation therapy for more than 7 days\n2. Currently prescribed PPI for regular daily use (patients receiving H2 receptor antagonists will not be excluded),\n3. Previous upper GI bleeding,\n4. Need for dual antiplatelet therapy,\n5. Contraindications to omeprazole (hypersensitivity to omeprazole, or other substituted benzimidazole PPIs, concomitant use with products that contain rilpivirine, significant drug interactions, up to the discretion of the site investigator),\n6. Life expectancy is less than 3 months.","65 Years",{"count":55,"type":20},360,"INTERVENTIONAL",[58],"PHASE3","The investigators are studying whether treatment with a proton pump inhibitor called omeprazole reduces gastrointestinal bleeding in older adults taking blood thinners for a blood clot (venous thromboembolism). The purpose of this study, a pilot study or a feasibility study, is to test the study plan and determine whether enough participants will join a larger study and accept the study procedures.",[61,62,25],"Venous Thromboembolism","Gastro Intestinal Bleeding",[64,65,66],"Omeprazole","VTE","GI Bleeding","2026-01-20",{"date":69,"type":37},"2026-01-22",{"date":71,"type":37},"2024-11-06",{"date":73,"type":20},"2028-03",{"name":75,"class":44},"Ottawa Hospital Research Institute",7,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":56,"phases":86,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},"100387045","phase-3-statins-for-venous-event-reduction-in-patients-with-venous-thromboembolism-100387045","NCT04319627","Statins for Venous Event Reduction in Patients With Venous Thromboembolism","SAVER","Inclusion Criteria:\n\n1\\. Symptomatic objectively confirmed proximal leg DVT (above the trifurcation of the popliteal vein) and\u002For PE (segmental or greater) diagnosed in the last 30 days.\n\nExclusion criteria\n\n1. Unable or unwilling to provide written informed consent;\n2. \\\u003C 18 years of age;\n3. Women of childbearing potential unwilling to use appropriate contraception;\n4. Currently prescribed a statin;\n5. A known medical history or current diagnosis of any of the following for which statins are indicated in secondary prevention:\n\n   1. Diabetes;\n   2. Abdominal aortic aneurysm;\n   3. Peripheral arterial disease;\n   4. Stroke;\n   5. Transient ischemic attack (TIA);\n   6. Myocardial infarction (MI);\n   7. Acute coronary syndromes;\n   8. Stable\u002Funstable angina;\n   9. Coronary or other arterial revascularization;\n6. Known diagnosis of hypercholesterolemia or dyslipidemia;\n7. Contraindication to rosuvastatin;\n\n   1. Known hypersensitivity or intolerance to statins;\n   2. History of muscle disorders or statin-related muscle pain;\n   3. Known liver disease (active liver disease, e.g. Hepatitis A, B, C, non-alcoholic fatty liver);\n   4. Chronic kidney disease (creatinine clearance \\\u003C 30ml\u002Fmin);\n   5. Currently pregnant or breast feeding;\n   6. Taking cyclosporine;\n   7. Taking atazanavir\u002Fritonavir;\n   8. Taking darolutamide;\n   9. Taking regorafenib;\n8. Unstable medical or psychological condition that would interfere with trial participation.",{"count":85,"type":20},2700,[58],"The standard or usual treatment for patients diagnosed with deep vein thrombosis or pulmonary embolism is treatment with blood thinners (called anticoagulants).\n\nWhile treatment of blood clots with blood thinners is effective, some research has shown that adding a statin (medication used to lower cholesterol) may give extra protection. It is thought that statins can improve how cells along the walls of the vein control inflammation, which can prevent new blood clots from forming.\n\nThe medication in this study, rosuvastatin, is approved in Canada for use as a cholesterol-lowering medication. The use of rosuvastatin in this study is considered investigational. This means that Health Canada has not approved the use of rosuvastatin as a treatment for blood clots. However, it has been approved for use in this research study.\n\nThe purpose of this study is to examine if adding a statin (rosuvastatin) to the usual blood thinner treatment will decrease the risk of another blood clot forming. The investigators also hope to discover if taking a statin reduces damage to your veins. To do this, some of the participants in this study will get rosuvastatin and others will receive a placebo (a substance that looks like the study rosuvastatin but does not have any active or medicinal ingredients). The placebo in this study is not intended to have any effect on your blood clot. A placebo is used to make the results of the study more reliable.",[61,25,89],"Post Thrombotic Syndrome",[91,92,93,65],"Rosuvastatin","Statin","PTS","2026-01-13",{"date":39,"type":37},{"date":97,"type":37},"2021-02-10",{"date":99,"type":20},"2028-04",{"name":75,"class":44},31]